<DOC>
	<DOCNO>NCT01159873</DOCNO>
	<brief_summary>Study Characterize Safety , Pharmacokinetics , Pharmacodynamics CEP-37251 Healthy Postmenopausal Women .</brief_summary>
	<brief_title>Single Ascending-Dose Study Characterize Safety , Pharmacokinetics , Pharmacodynamics CEP-37251 Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>The subject postmenopausal woman age 40 year great less 75 year . The subject ambulatory healthy judge medical examination , medical history , clinical chemistry , hematology urinalysis screening . The subject body weight great 50 kg 100 kg body mass index ( BMI ) 18 35 kg/m2 ) . The subject normal clinically acceptable ECG . The subject willing give write informed consent prior studyrelated procedure conduct . The subject willing able comply study restriction remain study center require inpatient period . The subject receive following medication within 6 month prior enrollment : hormone replacement therapy selective estrogen receptor modulator ( SERM ) therapy raloxifene elemental calcium supplementation &gt; 1.5 g/day Vitamin D supplementation &gt; 1000 IU per day calcitriol Vitamin D analog ( eg , alfacalcidol , doxercalciferol , paricalcitol ) calcitonin parathyroid hormone chronic use glucocorticoid NOTE : Acute use glucocorticoid may permit consultation medical monitor occur minimum 6 week prior enrollment anabolic steroid The subject receive bisphosphonates fluoride within 12 month prior enrollment . The subject follow concomitant condition : hypo hyperthyroidism . NOTE : Subjects treat hypothyroidism normal thyroid parameter may allow participate study discretion investigator medical monitor . hypo hyperparathyroidism recent fracture ( within 6 month ) osteomalacia , Paget 's Disease , osteopetrosis , osteogenesis imperfect , bone disease rheumatoid arthritis psoriatic arthritis acute osteoarthritis gout chronic kidney disease renal failure define eGFR ( MDRD equation ) 30 mL/min/1.73 m2 le The subject receive immunosuppressant drug . The subject currently participate another investigational study receive investigational drug within 60 day dose study drug . The subject evidence severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , psychiatric , cerebral disease , malabsorption syndrome . The subject known history evidence malignancy , lymphoproliferative , neoplastic disease exception successfully treat basal squamous cell carcinoma skin cervical intraepithelial neoplasia . The subject substantial change level physical activity participate intense physical activity ( e.g. , marathon training ) within 6 month prior dose study drug . The subject clinically significant disease disorder factor , substance abuse , opinion investigator , make subject ineligible participation study . The subject know suspected hypersensitivity idiosyncratic reaction compound present study drug placebo . The subject habitually consume , within past 2 year , 21 unit alcohol per week , history alcohol , narcotic , substance abuse define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) . NOTE : A unit alcohol equal approximately 30 ml spirit , 100 ml wine , 260 ml fullstrength beer . The subject , within 2 week administration dose study drug , clinically significant excessive consumption coffee , tea , and/or caffeinecontaining beverage food ( i.e. , 600 mg caffeine per day , 5 cup coffee per day ) , combination beverage food . The subject , within 4 week dose study drug , clinically significant illness , within 1 week dose study drug , acute illness , screen day dose study drug , symptom clinically significant acute illness . The subject , rest 5 minute , elevate blood pressure ( define systolic blood pressure 140 mm Hg subject ≤50 year age 155 mm Hg subject &gt; 50 year age and/or diastolic blood pressure 90 mm Hg ) low blood pressure ( define systolic blood pressure le 90 mm Hg and/or diastolic blood pressure le 45 mm Hg ) . The subject , rest 5 minute , pulse less 45 beat per minute ( bpm ) . The subject , rest 5 minute , pulse 90 bpm subject ≤50 year age pulse 100 bpm subject &gt; 50 year age . The subject positive test result hepatitis B surface antigen ( HBsAg ) antibodies hepatitis C human immunodeficiency virus ( HIV ) . History clinically important drug and/or vaccine allergy . The subject receive immunization live live attenuate vaccine within 3 month prior dose study drug immunization live live attenuate vaccine plan within 3 month dose study drug . The subject ongoing active systemic infection require treatment history severe infection , hepatitis pneumonia , 3 month prior dose study drug . Less severe infection 3 month prior dose study drug permit discretion investigator medical monitor . The subject positive alcohol serum , urine , breath test result positive urine drug screen ( UDS ) .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>